– USA, WA – Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Wendy L. Yarno to its board of directors. Ms. Yarno has more than 30 years of experience in the pharmaceutical industry as a public company director and product commercialization team leader, including 26 years with Merck & Co. Inc.

While at Merck, Ms. Yarno held positions of increasing responsibility with a focus on drug development, regulatory strategy, market development, global product strategy and product lifecycle management. Most recently until her retirement in 2008, she was chief marketing officer with oversight of a global team that handled pre- and post-launch product commercialization activities for more than 20 therapeutic areas. Before this, she served in several areas, including as general manager of the cardiovascular/metabolic business unit in the U.S., executive vice president of worldwide human health marketing, the leader of human resources and one of the top executives in both managed care and sales organizations. Earlier in her career she was vice president of the women’s health care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.

Ms. Yarno has served on the boards of emerging biopharmaceuticals and medical technology companies, including St. Jude Medical Inc., Medivation Inc., Durata Therapeutics Inc., ADial Pharmaceuticals LLC., and PluroGen Therapeutics LLC. She currently serves on the boards of Aratana Therapeutics Inc. and MyoKardia, Inc. Ms. Yarno holds a bachelor’s degree in business administration from Portland State University and a master’s degree in business administration from Temple University’s Fox School of Business.

“Wendy brings to our board highly relevant experience from her work in developing and launching best-in-class pharmaceuticals as well as helping to shape the directions of emerging companies,” said Randall C. Schatzman, Ph.D., Alder’s president and chief executive officer. “We are delighted to have her join us and welcome her guidance as we position Alder for leadership in the migraine prevention category with eptinezumab. We are moving closer to bringing a best-in-class therapy for migraine prevention to patients in need that we believe will change how this debilitating condition is addressed. The Alder team is focused on our progression of eptinezumab through pivotal studies and our BLA submission that is squarely in our sights for 2018.”

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

For more information : http://www.alderbio.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.